Metagenomi Therapeutics, Inc. MGX 深 沪
等待开盘 11-13 09:30:00 美东时间
0.714
-0.042
-5.59%
华盛通- 最 高0.83
- 今 开0.825
- 成交量 18.22万股
- 最 低 0.7001
- 昨 收 0.7563
- 总市值 2699.32万
- 52周最高 1.87
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 0.60
- 委 比 84.41%
- 总股本 3780.57万
- 历史最高 12.74
- 量 比 0.64
- 振 幅 17.18%
- 历史最低 0.60
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
08-11 21:09
Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $(257.000 thousand...
08-11 04:26
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5
Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.
07-07 18:59
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.
05-12 21:27
Metagenomi Q1 EPS $(0.61) Misses $(0.55) Estimate, Sales $1.248M Miss $5.925M Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 10.29 percent increase over losses of $(0.68) per share from the
05-12 04:23
Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced a publication
04-16 19:04
Metagenomi Therapeutics Q4 Earnings Assessment
The earnings results for Metagenomi Therapeutics (NASDAQ:MGX) for Q4 were made ...
03-06 05:14
